安徽女性内生殖器解剖模型双鸭山高级静脉输液腿模型,浙江下颌下三角解剖模型,湖北KAR/XDJH200高级心电监护训练模拟人,南宁智能推拿手法参数测定系统,崇左高级灌肠和辅助排便训练模型,石家庄产后出血训练模型,西藏不锈钢骨骼箱

BEIJING, Jan. 6 (Xinhua) -- Beijing will offer residents 20,000 rental bikes this year to ease the city's notorious traffic jams, according to authorities with the Beijing Municipal Commission of Development and Reform.Five hundred rental kiosks will be set up around the city to offer residents over 20,000 rental bikes, the commission said.Beijing has also proposed creating new bike lanes in some areas, including main streets, historical and cultural conservation areas and some major business districts, from 2011 to 2015, according to the commission.The capital city currently has about 5 million vehicles on its roads, leading to serious traffic congestion that frustrates the city's residents on a daily basis."A lack of bike lanes is the reason why I refuse to ride a bike. Bikes and vehicles are using the same lanes, and that frightens me and makes me feel unsafe," said Beijing resident Song Tao.People often park cars on the city's existing bike lanes, pushing cyclists onto the vehicles' lanes, said Song.To ease traffic congestion, Beijing has made various efforts to encourage people to opt for modes of public transportation.On Dec. 31, Beijing opened three new subway lines, bringing the number of subway lines in Beijing to 15, with a total length of 372 kilometers, said Beijing Metro Spokesman Jia Peng.Beijing will open four more subway lines in 2012, according to information released at a rail transit construction mobilization conference.Amid other measures to ease traffic in 2011, city authorities decided to allow only 240,000 vehicles to be registered annually, slashing the new car registrations by two-thirds from the 2010 level.Meanwhile, vehicles are banned from roads one day each week according to license plate numbers.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

WASHINGTON, Oct. 13 (Xinhua) -- U.S. researchers have corrected sickle cell disease in adult laboratory mice that had been bred to have the inherited blood disorder by activating production of a special blood component, according to a study published online Thursday in the journal Science.Sickle cell disease results from an abnormality in hemoglobin, the protein found in red blood cells that is responsible for transporting oxygen throughout the body. People living with sickle cell disease have two copies of an altered gene that produces sickle hemoglobin instead of normal adult hemoglobin. Sickle hemoglobin changes shape after releasing its oxygen, causing the red blood cell to become stiff, misshapen and sticky, and slowing blood flow to tissues. This process damages organs and causes pain.The study tested a new approach to increasing the production of a third form of hemoglobin -- fetal hemoglobin. Production of fetal hemoglobin predominates before birth, but turns off thereafter as adult hemoglobin production takes over. People with sickle cell disease are unable to make normal adult hemoglobin, and instead make sickle hemoglobin starting in infancy.An elevated level of fetal hemoglobin within the red blood cell reduces the tendency of sickle hemoglobin to change the shape of red blood cells. Considerable research has shown that the drug hydroxyurea increases production of fetal hemoglobin and reduces the number of pain crises and other complications of sickle cell disease in adults and children. However, not all patients respond well to hydroxyurea, and adverse side effects are a concern.The current study explores a more targeted approach to increasing fetal hemoglobin production. It builds upon earlier studies that discovered a protein called BCL11A normally suppresses the production of fetal hemoglobin soon after birth. The researchers viewed the BCL11A protein as a target for therapy and decided to see what would happen if they blocked production of the protein.The paper details how the research team silenced the mouse gene that produces the BCL11A protein in mice with sickle cell disease. Silencing the gene turned off production of the BCL11A protein and allowed the adult mice to continue to produce fetal hemoglobin. It appears to have eliminated disease symptoms without affecting other aspects of blood production."This discovery provides an important new target for future therapies in people with sickle cell disease," said Susan Shurin, acting director of the U.S. National Heart, Lung, and Blood Institute, which co-funded the study. "More work is needed before it will be possible to test such therapies in people, but this study demonstrates that the approach works in principle."Approximately 100,000 Americans live with sickle cell disease. It is most prevalent in people of African, Hispanic, Mediterranean, and Middle Eastern descent. There is no widely available cure for sickle cell disease. Bone marrow transplants have cured some patients, but the treatment is not without risk and most patients do not have relatives who can donate compatible and healthy bone marrow to them.

LAS VEGAS, the United States, Jan. 12 (Xinhua) -- NVIDIA, the computer chip manufacturer best known for its high performance graphics processors, is looking to make further inroads with the automobile industry by integrating its new Tegra 3 mobile processors in upcoming vehicle models.At the 2012 International Consumer Electronics Show (CES), NVIDIA and Audi announced that all models from the German auto manufacturer in 2013 will use Tegra 3 quad-core processors to power their in-car digital systems.These processors, which are traditionally found in smartphones and tablets, will support the vehicle's digital systems at lower energy rates and also allow for shorter lead times in getting concepts to market.In addition to powering infotainment systems that allow for web browsing and Google Earth integrations, they will also give automakers the ability to replace traditional dashboards with instrument cluster systems, or digital dashboards."By leveraging technology from the very latest smartphones and tablets, Audi is leading the market with innovations that enhance safety and make driving more enjoyable," said Ricky Hudi, the company's chief executive engineer, at Audi's official conference at CES.For Audi, this means that they will be able to offer cars like the next-generation A3 model beginning in 2013, which features an integrated touchpad system and mounted monitor with the ability to render 3D imaging. Current 2012 Audi vehicles house the Tegra 2 processor."It's a natural progression with people getting so accustomed to mobile and expecting it from your automobiles as well. Partnering really closely with automotive OEMs enable us to help them realize the driver experience they're looking to deliver," said Phillip Hughes, NVIDIA's director of automotive sales and business development, in an interview with Xinhua.In addition to Audi, Tesla and Lamborghini will also be including the newest NVIDIA Tegra 3 processor in upcoming models. At this year's CES, Lamborghini is showcasing the Lamborghini Aventador, a nearly 700 horsepower vehicle with the capability of going from 0 to 60 miles per mile in less than five seconds."NVIDIA technology is enabling us to do more with our vehicles and gives our cars the ability to have the technology you'd expect from a car like this," said Kelly Snyder, an event manager with Lamborghini, to Xinhua. The retail price point for the Lamborghini Aventador starts at 382,000 U.S. dollars.More than just powering the car's digital experiences, however, integrating NVIDIA's processors will help the auto manufacturer build better cars by reducing the power to weight ratio that is a key consideration in manufacturing higher performing cars."By moving elements like the odometer to a digital dashboard platform, it reduces the power to weight ratio that is so critical to the design and manufacturing of automobiles like the Lamborghini," explained Snyder.NVIDIA also expects that the integration of these processors will bring the development cycle of the automotive industry up to speed with the consumer electronics industry through Virtual Computing Modules (VCMs) powered by the Tegra 3. These VCMs allow auto manufacturers to quickly prototype and ship consumer technology innovations to automobiles, reducing a development lifecycle that once took seven years, to roughly a year."At the end of the day, our goal is to help automotive OEMs bridge the gap between OEM and consumer technology," said Hughes.

BEIJING, Nov. 7 (Xinhuanet) -- A huge asteroid will pass closer to Earth than the moon on Tuesday, but experts say there is no cause for alarm.Asteroid 2005 YU 55 will pass about 300-thousand kilometers from the earth. The giant space rock is about 400 meters in diameter. The close encounter will occur at 23:28 Greenwich Mean Time. Computer models showing the asteroid’s path for the next 100 years show there is no chance it will hit Earth during that time.Previous studies show the asteroid is what is called a C-type asteroid that is likely made of carbon-based materials and some silicate rock.